

TABLE OF CONTENTS

July 16, 2007

No. 2049

BUSINESS

- 1 Nippon Shinyaku to Rebuild Pipeline with Niche Products: New President Maekawa
 - No Interest in Embarking on Generic Business at the Moment
 - Orodispersible Version Added to the Gaslon N Series
- 3 Takeda's MRs to Deal with All of Its Products: Mr Yamanaka
 - Takeda Will Not Be Able to Detour Wholesalers
- 3 Nippon Kayaku Aims at Sales of ¥10 Billion with Generics
- 4 Nexavar to Become Standard Therapy for Hepatocellular Carcinoma
 - Benefits of High-Dose Avastin Must Be Demonstrated: Dr Wagner
- 4 Blopress Ranks No. One 3 Times in 3 Years: Top-100 Drug Ranking
 - ARBs, Drugs in the Field of Orthopedic Surgery Take Off
- 8 Eyeforpharma Sales Force Effectiveness Japan 2007
 - MR Efficiency Needs to Be Improved
 - Control-Oriented SFE Undesirable in Japan: Mr Shigihara of Daiichi Sankyo
 - SFE Should Be Fully Utilized to Upgrade MRs: Mr Okada of IMS Japan
 - Daiichi Sankyo Has No Marketing Division: Mr Takada
 - All MRs Given Access to Other MRs' Daily Business Reports: MPC
 - Large Gaps between Office Managers and MRs: Mr Takahashi of Kowa
 - 2/6/2 Law Applies to MR Teams
 - One-on-one Training for Average MRs: Kowa
 - Poor MRs May Improve Performance by Imitating Outstanding MRs: NBI
 - Relocation May Improve MR's Performance: Mr D. Feldman of Banyu
 - Swiss MRs Visit Doctors Only 4 Times a Year: Mr Armstrong of Novartis
 - Direct Observation More Reliable than Data: Mr Hirai of GSK
 - FLMs Should Spend 70% of Time Coaching MRs: Mr Nishitani of Schering-Plough
 - Provide Solid Information to Acquire Many Prescriptions: Dr Nozaki
- 10 Banyu's Prominent Shows Highest Awareness Rate: Survey
- 11 Diovan Maintains 2nd Place for 2 Months in a Row in Rep Track Survey
- 10 **BUSINESS NEWS IN BRIEF**
 - Kaken Acquires Exclusive Rights to Integrin Antibody

GENERICS

- 12 420 Generics Receive NHI Price Listing

- Risperidone Sees 1st Generics
- Cetirizine Sees the Largest Number of Generics
- Sawai Receives Listing for Largest Number of Products
- Tanabe Has 9 Products (4 APIs) Price-Listed
- Elmed Eisai Has 4 Generics (3 APIs) Listed
- Kyorin Launches 7 New Generics (4 APIs)
- Nippon Kayaku Launches Fluorouracil Booster
- Baxter Launched Generics of Granisetron
- aRigen Launches Its First Generic Products
- Teva's Entry to Be Delayed One Year

REGULATORY

- 18 10 APIs Recommended for Approval by CDFS's Dept. on Drugs
- 18 *Ryukaikon* to Focus on Business between Makers and Wholesalers
 - Survey on Price Agreement to Be Conducted in July
- 18 **REGULATORY NEWS IN BRIEF**
 - Nippon Organon, Meiji Seika Apply for Mirtazapine
 - Plavix Granted "Fast Track" Status

R&D

- 19 AntiCancer Inc. Opens Bioimaging Research Lab in Osaka
- 19 Astellas, Kyoto Univ. Start Collaborative Drug Discovery
- 20 Draft Guidance for MD Studies Presented
- 20 **R&D NEWS IN BRIEF**
 - Micardis Controls Risky Morning BP: Astellas, NBI
 - Eliminate Drug Lag Utilizing Core Hospitals for Clinical Trials

MEDICAL FACILITIES & NURSING CARE

- 21 Expenditures under NHI Programs in 2006 Rose Only 0.5%
- 21 Research to Prevent Progression of CKD to Dialysis to Start
- 22 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - More Municipal Hospitals Interested in DPC
 - Policy on Reimbursement of Drugs Used to Prevent Complications Clarified
 - Review of Advanced Medical Technologies to Be Completed in October
 - *Koroshō* Predicts Excess of 13,000 Pharmacists in 2028
 - *Bungyo* Rate Up 2.3 Points to 56.8% in Nov. 2006
- 23 **Survey**
 - Adhesives Most Preferred Dosage form of Narcotics for Cancer Pain
 - Ideal MRs Do Not Smoke: So-net M3/SSRI